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Prologue
Quote from A Scientist about 25 years from now:
ʺInstead of creation of offspring by chance we can create offspring by choice.ʺ

Introduction
The world literature circle was abuzz in 1932 when Aldous Huxley published his
seminal book “Brave New World”. He painted the efforts of a totalitarian state to
lab manufacture “sub‐human” people who would be capable of work but not of
independent thought. Though the plot was set almost 500 years in the future, the
author may not have envisioned that within a century of his writing scientists
would embark on developing technologies that could potentially set the road for
ʺdesigner babiesʺ in the future. The recent availability of the simple, yet highly
effective, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)
technology ‐‐ which is taking the scientific world by storm – provides the
preliminary steps in the genome editing (making specific changes at targeted
genomic sites) efforts of any biological organisms. The recent report of Chinese
scientists’ use of the CRISPR system to rectify the mutation in a gene that causes
beta‐thalassemia disease in human embryos highlights the progression the
scientific world is making in the realm of genome editing in germline (Liang
et al. 2015). The scientific community has now widely accepted the fact that it is
not a matter of if, but when, the Nobel Prize will be awarded for the
development of this groundbreaking technology.
*Author for correspondence: <hullah@howard.edu>. 1Department of Biochemistry and
Molecular Biology, Howard University, 420 W. St., NW, Washington, DC 200592.
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Background on Genome editing tools
The ability to manipulate genes is important in elucidating their functions. The
knowledge gained from these studies can be applied to treating diseases, such as
alleviating certain metabolic defects, or to improve the quality of offspring, like
in modifying plants to have higher crop yields.
Endonuclease‐based targeted genome editing methods that emerged in the
past decade are revolutionary molecular biology tools that have gained the
attention of researchers around the world. Zinc Finger Nucleases (ZFNs),
Transcription Activator‐Like Endonucleases (TALENs) and CRISPR/Cas9
systems are programmable site‐specific nucleases. Each of the nucleases act by
inducing Double Strand Breaks (DSB) in DNA and result in the activation of
error‐prone Non‐Homologous End Joining (NHEJ) and/or Homology Directed
Repair (HDR) at the originally targeted genomic locus (Gai et al. 2013).
Activation of the NHEJ or HDR process is then utilized to induce diverse
genome manipulations in a sequence‐specific manner, such as gene
activation/inactivation, sequence deletion, element replacement and
chromosomal rearrangement. Unlike previous gene therapy tools that add or
insert an exogenous DNA copy into the target cell nucleus or genome, which
may give rise to side effects such as insertional mutations and non‐physical
expression of proteins, programmable nucleases use a ‘cut‐and‐paste’ strategy to
remove the defect and install the correct version (Xiao‐Jie et al. 2015). This
represents a preferable tool for gene therapy. The simplicity of the system is
based on the introduction/injection of a Guide‐RNA (gRNA) containing the
target gene sequence (20 bp) and an endonuclease (Cas9) protein or mRNA into
the cell. The injected molecules induce double strand DNA breaks in the targeted
gene and the cell then activates NHEJ or HDR to repair the breaks and during
the repair process induces the desired modification in the gene (see the schematic
below). Compared to the protein based systems, the CRISPR/Cas9 system is
more specific, convenient, efficient and is able to induce or rectify mutations in
multiple places simultaneously in a wide range of organisms, including the
human embryo. CRISPR/Cas9 has quickly become the most powerful genome
engineering tool available in the field of biomedical as well as Plant Research.
Historical perspective of CRISPR
CRISPR/Cas system was discovered in bacteria as their adaptive immune
response mechanism against foreign DNA such as viral DNA. CRISPRs are
clustered genetic elements in the bacterial genome that contain parts of viral
DNA acquired form the past viral infections. These snippets of DNA are called
‘spacers’ (Fig. 1). CRISPR was first described in E. Coli cells by Ishino and
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Shinagawa (1987). Ishino discovered 14 repeating sequences which were
regularly spaced but were random in sequence. The random arrays, along with
conserved upstream gene sequences, were later found in a vast array of bacterial
cells. By 2005 it was reported that the spacers often contained exogenous DNA,
specifically, plasmid or phage DNA, resulting in the hypothesis that CRISPR
played a role in bacterial immunity due to the fact that the invading phages are

Fig. 1. Schematic of the type II CRISPR‐mediated DNA double‐strand break in invading DNA.
The type II CRISPR locus contains a cluster of four genes, Cas9, Cas1, Cas2, and Csn1, as well as
two noncoding RNA elements, tracrRNA and a characteristic array of repetitive sequences (direct
repeats) interspaced by short stretches of non‐repetitive sequences (spacers, 30 bp each). Each
spacer is typically derived from foreign genetic material (protospacer)and drivesthe specificity of
CRISPR‐ mediated nucleic acid cleavage. In the target nucleic acid, each protospacer is associated
with a protospacer adjacent motif (PAM) whose recognition is exclusive to individual CRISPR
systems. Type II CRISPR system carries out targeted DNA double‐strand break (DSB) in
sequential steps. Step 1, the pre‐crRNA array and tracrRNA are transcribed from the CRISPR
locus. Second, tracrRNA hybridizes to the direct repeats of pre‐crRNA and associates with Cas9 as
a duplex, which mediates the processing of the pre‐crRNA into mature crRNAs containing
individual truncated spacer sequences. Third, the mature crRNA/ tracrRNA duplex directs Cas9 to
the DNA target consisting of the protospacer and the requisite PAM via heteroduplex formation
between the spacer region of the crRNA and the protospacer DNA. Finally, Cas9 mediates
cleavage of target DNA upstream of PAM to create a DSB within the protospacer‐ thereby
inactivating any invading virus. (Adapted from www.biomart.cn).

recognized based on the similarity of their DNA sequence to the spacer
sequences (Bolotin et al. 2005, Mojica et al. 2005). The hypothesis of a role in
bacterial immunity was ultimately confirmed by evidence that there was a direct
correlation between viral infection of bacteria and the number of spacers
(Magadán et al. 2012). When a virus insert its DNA into the bacteria, the
transcribed ‘spacers’, which are about 60 nucleotides long RNA molecules
complimentary to the piece of viral DNA, will bind to the invading viral DNA
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and by using the endonuclease‐like Cas9 (CRISPR associated protein 9) it can
make double strand breaks in the targeted DNA thereby destroying the viral
DNA. Scientists realized that by expressing DNA spacers specific to any gene
sequences and the corresponding endonuclease like Cas9, a double stranded cut
can then be induced in the target gene. The cells then try to repair the DSB by
the error prone NHEJ or by HDR process. Both of the repair mechanisms can be
utilized to introduce/rectify mutations in the double stranded cut DNA without
the need for the spacers DNA to get integrated in the genome of the target
organism. Researchers quickly realized how beneficial this natural defense
mechanism could be if it was adapted for experimental purposes and many set
out to determine the exact method by which CRISPR/Cas9 worked.
Mechanism of CRISPR mediated genome editing
The CRISPR defense mechanism as described above consists of three classes, all
based on the CRISPR associated proteins (Cas proteins). The type II class is the
most widely studied and what will be described in this review. By 2012
scientists became intimately aware of an adaptive defense system in certain
bacteria (Magadán et al. 2012). At the time it was known that upon detection of
exogenous DNA, bacterial cells responded by degrading the foreign/invading
DNA from virus or plasmid. The resulting fragments (spacer) were then
incorporated into the bacteria’s genome, essential for the recognition of repeat
invasions. One or more existing conserved spacers are lost to prevent CRISPR to
expand unchecked (Horvath et al. 2008, Tyson et al. 2008).
A repeat invasion by a virus or plasmid results in the transcription of the
type II CRISPR locus, producing CRISPR associated proteins, Cas9 in particular,
and two single‐stranded RNA transcripts (Fig. 1). One of the RNA transcripts, is
referred to as a precursor CRISPR RNA (pre‐crRNA) and it contains the spacer
sequence, therefore, it is complementary to the protospacer region (target region)
of the exogenous DNA. The other transcript, tracer RNA (tracrRNA) binds to a
complementary repeat sequence on the pre‐crRNA. This newly formed double‐
stranded RNA prompts RNaseIII to cleave the pre‐crRNA, producing a mature
crRNA/tracrRNA complex. The crRNA/tracrRNA complex binds with the Cas9
nuclease to create a tracrRNA/crRNA/Cas9 complex.
A short sequence referred to as a protospacer‐adjacent motif (PAM) located
on the immediate 3’ end of the guideRNA (tracrRNA/crRNA together)
recognition sequence also helps with target recognition. The PAM sequence
varies by the species of the bacteria from which the Cas9 was derived. The most
widely used Type II CRISPR system is derived from S. pyogenes and the PAM
sequence is NGG located on the DNA strand complementary to the gRNA
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bound DNA strand. In addition to PAM, a short 12 to 15 nt sequence (seed
sequence) upstream of the PAM sequence also helps with the recognition
specificity. It is the job of Cas9 to scan the DNA for a PAM sequence and unwind
the DNA when the PAM sequence is located. If there is complementation
between the crRNA and the DNA, the complex will bind the DNA about 3 base
pairs from the 5’ end of the PAM sequence and then Cas9 creates a double strand
break (DSB) in the target DNA to silence the exogenous DNA. This nicked DNA
can be repaired either by NHEJ or by HDR. NHEJ repair pathway results in
insertions or deletions (InDels) where double strand breaks occurred which leads
to a disruption in the open reading frame of the target locus. The HDR pathway
needs a repair DNA template to fix the DSB and when a repair template is
present, the result is integration of the sequence of DNA on the repair template
into the DSB site, thereby replacing the genomic DNA in that region (Figure 2).
Additional studies led scientists to realize that the programmed
crRNA/tracrRNA complex could be replaced by an artificially programmed
chimeric RNA, referred to as a guide RNA (gRNA) and that to accomplish
genome editing, a cell could be simultaneously transfected/injected with the
gRNA, the Cas9 nuclease, and in case of HDR ‐ a donor DNA template.
Before attempting to explore Figs 2 and 3, which describe the detailed
mechanism of the CRISPR process, the readers are advised to view the excellent
animation on CRISPR developed by the McGovern Institute for Brain Research at
MIT (https://www.youtube.com/watch?v=2pp17E4E‐O8). Fig. 2 presents the
generalized scheme of CRISPR‐Cas9 mediated gene editing in a simplified way.
After the gRNA/Cas9 complex is introduced in the cell, the complex is recruited
to the target sequence by the base‐pairing between the gRNA sequence and the
complementary genomic DNA target sequence. For successful binding of Cas9,
the genomic target sequence must also contain a Protospacer Adjacent Motif
(PAM, blue region in Fig. 2A) sequence immediately following the genomic
target sequence. The binding of the gRNA/Cas9 complex localizes the Cas9 to the
genomic target sequence such that the wild‐type Cas9 can cut both strands of
DNA causing a Double Strand Break (DSB). Cas9 will cut 3 ‐ 4 nucleotides
upstream of the PAM sequence. Once cut, the DSB can be repaired through one
of two general repair pathways: (1) the Non‐Homologous End Joining (NHEJ)
DNA repair pathway or (2) the Homology Directed Repair (HDR) pathway. The
NHEJ repair pathway often results in inserts/deletions (InDels) in the DSB site
that can lead to frameshifts and/or generation of premature stop codons,
effectively disrupting the open reading frame (ORF) of the targeted gene. The
HDR pathway requires the presence of a repair template, which is used to fix the
DSB. HDR faithfully copies the sequence of the repair template to the cut target
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sequence. Specific nucleotide changes can be introduced into the targeted
genomic loci by the use of HDR with an appropriate modified repair template.

Fig. 2. Generalized scheme of CRISPR‐cas9 mediated gene editing. After the introduction of gRNA
containing complementary sequences to a targeted gene and Cas9 in the nucleus of target
organism, the gRNA binds to the target sequence (A), the target DNA is cut by the Cas9
endonuclease (B). If no template DNA is available, NHEJ method is used by cells to repair the
double stranded cut by incorporating/deleting random nucleotides in the cut site‐resulting
insertion/deletions in the target DNA (C1). If a donor DNA with a sequence that is intended to be
incorporated in the cut site is used as a template, the cell will use the template DNA to do
homologous recombination (as the donor DNA will have left and right flanking homologous DNA
sequence) resulting in the replacement of the cut DNA with the donor DNA effecting the intended
changes (C2).

In order to maximize the effect of gene disruption, target sequences should
be chosen near the N‐terminus of the coding region of the gene of interest.
Typically, the target sequence is selected to introduce a DSB within the first or
second exon of the gene. It is important not to design targets to introns (non‐
coding regions), as repair of the DSB in that region will not disrupt the target
gene. When designing a repair template for genome editing by HDR, it is
important that the repair template does NOT contain the target sequence
followed by the PAM sequence or the template itself will also be cut by the Cas9.
Changing the sequence of the PAM in the repair template should be sufficient to
ensure it is not cut by Cas9. Finally, it is imperative to note that the changes
introduced by use of the CRISPR system are permanent to the genomic DNA of
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the organism (more can be found here: https://www.addgene.org/CRISPR/
guide/).

Fig. 3. Introduction of gRNA with sequences complementary to the 3’‐CTCGTTATTTT‐5’ along with
cas9 protein in the cell induces a double stranded cut at 3 ‐ 4 bp upstream of the PAM sequence
(TGG)‐ shown with the scissors. Cells try to use error‐prone NHEJ to repair the double strand cut
in the DNA. This repair mechanism does not use any template DNA to recombine but inserts (G/C
in the figure) or deletes (AA/TT) random sequences in the cut to fill it up‐ effectively making the
wild type gene sequence disrupted (left panel). In case, there is a need to rectify a mutation in a
gene (C in number 4th position within the complimentary sequence to T in the corrected version),
one will have to provide a donor DNA (single or double stranded) with the corrected sequence
flanking left and right homologous sequences of the gene. Due to the homology of the left and
right flanking sequences, the donor DNA will be used for homology recombination by the cell to
fill up the double stranded cut in the DNA. The homology recombination will result in the
exchange of DNA with the mutated sequence with the donor DNA containing the adjusted
sequence‐ resulting in the correction of mutation (right panel).

Fig. 3 represents a hypothetical gene sequence that is disrupted by a deletion
or insertion of random nucleotides (left panel) or uses a donor DNA to rectify a
specific mutation (right panel). The general steps one would take to edit a gene
are to first identify a 23 bp genomic site of the form 5’‐N20NGG near the intended
target site (ideally +/‐ 50 bp). These bases may reside on the plus or on the minus
strand. Using NCBI BLAST program, make sure your selected 23 bp genomic
sequence is unique in the genome and that there are preferably none or very few
sequences similar to the selected sequence at other locations in the genome.
Putative target sites can also be identified by using an online tool such as ZiFit
(http://zifit.partners.org/ZiFiT/ChoiceMenu.aspx) or CRISPR design (http://
crispr.mit.edu). If you choose to scan for sites manually, you should still check
your gRNA design for potential off‐target effects by using ZiFit, CRISPR design
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tool, or another algorithm designed to predict off‐target binding and
mutagenesis. Scientists try to avoid gRNAs that have potential off‐target sites
with fewer than 3 mismatched bases (or fewer than 2 mismatched bases for a
shorter, 17 bp guide). Once the 23 bp site has been identified, it is incorporated
into a plasmid containing other conserved components needed for CRISPR to
function, such as a U6 promoter, guide RNA scaffold, and terminator sequence.
The whole sequence can be synthesized commercially by a company, like IDT,
and cloned in a plasmid backbone. The resulting plasmid can be used to
transcribe gRNA in vitro, and the gRNA and Cas9 protein can now be injected in
to the cell intended for editing. In the example of Fig. 3, once the gRNA and Cas9
are introduced, the Cas9 makes a double stranded cut about 3 bp upstream of the
TGG PAM sequence (scissors cut in the figure). A cell that attempts to repair the
double stranded cut with the NEHJ pathway may result in a small genomic
deletion (AA/TT in this example) or a new insertion (G/C). Either of these
activities would disrupt the open reading frame‐ effectively disrupting the target
gene. In the case of rectifying a mutation in the genome (for example, in Fig. 3,
altering mutant (C/G) to wild type (T/A), a donor DNA (single or double
stranded) with the wild type sequence flanking homologous sequences of the
target gene is introduced. The cell can then attempt to repair the double stranded
cut with the availability of the template DNA (donor DNA). Using homology
based recombination, the template DNA with the wild type sequence replaces
the cut site DNA‐ restoring the mutation to the wild type sequence.
Application of CRISPR
CRISPR application is currently leaning toward genome editing. Many diseases
are genetic in nature, be it inheritable or acquired genetic mutations. CRISPR
appears to be an effective technique that will allow scientists to adequately edit
genes to cure diseases. Sickle cell anemia is a great example of a disease in which
mutation of a single base mutation (T to A) could be edited by CRISPR and the
disease cured. The case is similar for plant species, where scientists desire, for
example, to knock‐out a gene that will result in an increase in a particular
nutritional content or in increased drought and/or pest resistance. Prior to the
discovery of CRISPR, genome editing depended mainly on zinc finger nucleases
and TAL effector nuclear (TALENs) techniques that are more laborious and lack
efficacy. With the CRISPR method scientist now have the ability to use vectors
containing, for example, a gRNA expression cassette with a suitable RNA
polymerase III promoter (U6 or U3) to edit targeted gene loci. Thus far, there has
been some success in this regard. Restriction enzyme site loss assays have been
used to confirm successful CRISPR‐mediated genome editing in model plants
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like Arabidopsis thaliana (Belhaj et al. 2015, Bortesi and Fischer 2015). Likewise, in
an effort to confirm that gene editing was at least possible, cells from rice plants
were transformed with vectors carrying CRISPR gateway vector targeting
CHLOROPHYLL A OXYGENASE 1 (CAO1) gene (Miao et al. 2013). These
examples at the very least confirm that a particular gene of interest was
successfully targeted. More importantly, it has been shown in Arabidopsis, rice
and tomato plants that the genetic changes induced by Cas9/gRNA were present
in the germline and segregated normally in subsequent generations without
further modifications (Bortesi and Fischer 2015). Ebina et al. (2013) reported that
CRISPR‐Cas9 can mutate long terminal repeat (LTR) sequence of HIV‐1 in vitro,
resulting in removal of the integrated proviral DNA from the part of the host
cells and a significant drop in virus expression. Chronic hepatitis B is one the
most common infectious diseases world‐wide, which can lead to liver cirrhosis
and cancer. Recently, a study by Seeger and Sohn (2015) showed that in HepG2
cells expressing hepatitis B virus (HBV), the introduction of CRISPR‐Cas9 system
resulted in both decreased hepatitis B core antigen expression which provides an
impetus for further research on the possibility of CRISPR‐Cas9‐mediated
hepatitis B prevention. In a mouse model of Duchenne muscular dystrophy
(DMD), an inherited X‐linked monogenic disease, CRISPR‐Cas9‐mediated gene
editing in the germline gave rise to genetically mosaic offspring with 2‐100%
somatic cells carrying the corrected version of the culprit gene (Long et al. 2014).
Studies by Wu et al. (2013, 2015) serves as another example where germline‐
manipulation with CRISPR‐Cas9 system in mice were capable of correcting both
the mutant gene and cataract phenotype in offspring initially caused by a one
base pair deletion in exon 3 of Crygc (crystallin gamma C) gene. In human
intestinal stem cells collected from patients with cystic fibrosis, the culprit
defective gene CFTR (cystic fibrosis transmembrane conductance regulator) was
rectified by homologous recombination during CRISPR‐Cas9 genome editing
while the pluripotency was retained as demonstrated by formations of organ‐like
expansions in cell culture (Schwank et al. 2013).
With regard to genome editing in plants, the CRISPR application does not
have the negative stigma that is associated with genetically modified organisms
(GMO). In fact, GMOs are banned in most European countries out of concern of
unforeseen side effects. However, unlike GMOs, CRISPR relies on endogenous
cellular mechanisms to silence or edit genes. Therefore, technically gene editing
under the CRISPR method is not classified as genomic modification‐ as no new
DNA is integrated in the host genome. The injected/transfected RNA/DNA and
protein get diluted by continuous cell division and eventually falls below the
level of detection. Most of the edits take place using cells own repair machineries;
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hence the resulting edited genome is not identified as genetically modified. The
result is that relative to GMOs less regulation and wider acceptance of CRISPR
editing is expected. However, scientists are actively discussing the ethical
aspects of this technology. Rudolf Jaenisch, MD, [a founding member of the
Whitehead Institute for Biomedical Research and, President of the International
Society for Stem Cell Research] expressed discontent at the rush toward the use
CRISPR for gene editing (Jaenisch 2015). Dr. Jaenisch acknowledged the benefits
of the science but questioned the circumstances that would justify its use in the
absence of more scrutiny. Furthermore, Dr. Jaenisch has requested a moratorium
to discuss the social and ethical issues. His remarks were made a few days after
Chinese researchers published studies in connection with the use of human
embryos to study the effectiveness of CRISPR in correcting thalassemia, an
inheritable disease that results in anemia (Liang et al. 2015).
Future directions
If the CRISPR technique is to get beyond public scrutiny and possible regulatory
demands, its off‐target mutations must be corrected or at least minimized to an
appreciable extent. Perfection of the off‐target mutations will go a long way to
quell such scrutiny. Currently, there are a couple of techniques that scientists are
using to improve target selectivity. First, Cas9 has two nuclease domains,
namely, Cas9 HNH and Cas9 RuvC (Shen et al. 2014). Researchers are currently
looking into nullifying one of the nuclease sites followed by transformation of
cells with two Cas9s; one with Cas9 HNH inactivated and the other with Cas9
RuvC. The mutated Cas9 proteins are referred to as Nickase, as they form single‐
stranded nicks in the DNA as opposed to double‐strand breaks. The technique
requires two individual gRNAs. The logic behind the Nickase protocol is that
single‐strand nicks are easily repaired without the creation of the mutations
associated with double‐strand break repairs (Fig. 3). Similarly, in 2014 Doudna ‐
co‐founder of the type II CRISPR technique indicated that conformational
changes occur in Cas9 upon binding to the gRNA, with additional
conformational changes upon binding to double‐stranded DNA (Doudna and
Charpentier 2014). Doudna speculated that modifications in the gDNA and/or
Cas9 could affect conformational changes enough to render Cas9 inactive upon
off‐target binding, thereby reducing off‐target mutations. Advances have also
been made by using completely inactivated Cas9s in order to perform an array of
techniques from physically blocking gene expression, by acting as a signaling
system, etc. The inactivated Cas9 is referred to as dead Cas9 (dCas9) and are
used in this regard (Agne et al. 2014). Dead Cas9 have been inactivated such that
they no longer possess nuclease activity. When a dCas9 is paired with a gRNA,
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the complex silences gene expression by simply base pairing with the target
gene, without cutting the DNA. Relative to RNAi, gene silencing with dCas9 is
more pronounced and takes place over a longer time period. DCas9 can also be
used as a signaling probe to locate and map specific genes. Of course, the future
direction of CRISPR has been enhanced with the creation of gRNA libraries and
computer programs to help with gRNA programming.
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